TABLE 3.

Treatment related adverse events.

Adverse events	Any grade	Grades 3–4
All (Treatment‐related)	62 (89.9%)	24 (34.8%)
Fatigue	35 (50.7%)	3 (4.3%)
Hypertension	32 (46.4%)	6 (8.7%)
Diarrhea	30 (43.5%)	2 (2.9%)
Decreased appetite	30 (43.5%)	2 (2.9%)
Hand and foot syndrome	26 (37.7%)	1 (1.4%)
Hypothyroidism	14 (20.3%)
Hyperbilirubinemia	10 (14.5%)	1 (1.4%)
Elevated transaminase	9 (13.0%)	3 (4.3%)
Nausea/vomiting	9 (13.0%)
Thrombocytopenia	8 (11.6%)	2 (2.9%)
Proteinuria	8 (11.6%)	2 (2.9%)
Peripheral edema	3 (4.3%)
Hepatic encephalopathy	2 (2.9%)	2 (2.9%)
Abdominal pain	1 (1.4%)
Immune‐related AE (irAE)	16 (23.2%)	2 (2.9%)
Reactive cutaneous capillary endothelial proliferation	10
Hepatitis	4 1	2
Interstitial pneumonia	1
Myocarditis	1
Dose reduction	15 (21.7%)
Drug interruption	5 (7.2%)
Hypertension	3
Diarrhea	2
Decreased appetite	2
Fatigue	2
Diarrhea	1
Hepatic encephalopathy	2
Grades 3 thrombocytopenia	2
Interstitial pneumonia	1